$ITGR

Integer Holdings Corp

No enriched coverage for $ITGR in the last 7 days.

$5.2M
Thor Kirk K
0%
See all $ITGR insider activity →
Low

Thor Kirk K sold $4.0M of ITGR

Thor Kirk K (Chief Human Resources Officer) sold 31,540 shares of Integer Holdings Corp (ITGR) at an average of $126.24 ($126.23–$126.25, $3.98M total) across 2 trades over 2026-09-14 to 2026-09-15.

KKR finalizes $2.1 billion loan to fund Integer acquisition

KKR & Co. (KKR) secured a $2.1 billion loan to finance its $5.7 billion acquisition of Integer Holdings (ITGR), with improved borrowing terms due to strong investor demand. The loan was priced at 2.5 percentage points above its benchmark, lower than initially discussed. The transaction is expected to close by the end of 2026, with Citigroup (C) leading the loan sale. KKR shares fell 1.9% on Friday, while Integer shares remained unchanged.

ITGR sentiment & insider activity

Recent ITGR coverage spans mergers & acquisitions, insider activity and corporate actions.

In the last 30 days, ITGR insiders filed 3 SEC Form 4 transactions — no purchases and 3 sales ($5.2M). The most active reporter was Thor Kirk K, Chief Human Resources Officer, with 2 filings.

What's driving ITGR

AlphAI scores every news story that mentions ITGR with an AI model for sentiment and relevance, and aggregates insider trades from Integer Holdings Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $ITGR

Score
$KKRHighAI 8/10

KKR finalizes $2.1 billion loan to fund Integer acquisition

KKR & Co. (KKR) secured a $2.1 billion loan to finance its $5.7 billion acquisition of Integer Holdings (ITGR), with improved borrowing terms due to strong investor demand. The loan was priced at 2.5 percentage points above its benchmark, lower than initially discussed. The transaction is expected to close by the end of 2026, with Citigroup (C) leading the loan sale. KKR shares fell 1.9% on Friday, while Integer shares remained unchanged.

$ITGRHighAI 9/10

How Could KKR's $5.7 Billion Buyout Reshape ITGR for Shareholders?

Integer Holdings (ITGR) agreed to a $5.7B buyout by KKR, offering $127 per share. The deal's completion depends on shareholder and regulatory approvals. ITGR withdrew its financial outlook and canceled its Q2 earnings call. If completed, ITGR will become private and delist from NYSE. ITGR's Q2 sales fell 2.6% YoY to $464.1M, with gross margin contracting to 24.3%.

$ITGRHighAI 9/10

51.8% premium on table in KKR deal for Integer (NYSE: ITGR), if shareholders approve

KKR-affiliated entities plan to acquire Integer Holdings (ITGR) for $127 per share, a 51.8% premium over the unaffected closing price. The deal requires shareholder approval and regulatory clearances. ITGR's board recommends voting in favor, with completion subject to customary conditions. If approved, ITGR will become a subsidiary of the buyer and cease trading on NYSE.

$ITGRHighAI 9/10

What Integer's Deal Means for Minnesota's Med Device Industry

Integer Holdings, a major medical device manufacturer, is being acquired by KKR for $5.7B. Integer supplies components to companies like Abbott, Boston Scientific, and Medtronic. The deal may impact Minnesota's med-tech industry, where Integer has significant operations. KKR's acquisition could lead to consolidation in the sector, with potential implications for competition and pricing. Integer reported $1.8B in revenue last year.

$KKRHighAI 9/10

KKR to Acquire Integer Holdings in $5.7 Bn All-Cash Deal

KKR will acquire medical device outsourcing company Integer Holdings in an all-cash deal valued at about $5.7 billion, paying $127 per share and assuming Integer’s outstanding debt, according to the companies. The offer implies a 4.78% premium to Integer’s Friday close. Integer shares rose 2.4% premarket. KKR said it will expand its healthcare portfolio.

$SUPNMed

Biotech funding rises 75% year-over-year, Braveheart surges

Macquarie said global biotech funding for the year through Aug. 7 rose 75% YoY, driven by IPOs up 235% and follow-ons up 138%. The XBI biotech index gained 7% in the week to Aug. 7. Braveheart Bio’s upsized IPO raised $382.5M and shares jumped 66%. Curium agreed to buy Lantheus for up to $8B, and Supernus and Indivior plan an all-stock merger.

Related tickers